What is the treatment for bradycardia (abnormally slow heart rate)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 21, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Bradycardia treatment should prioritize atropine 0.5 mg IV as the first-line medication, which can be repeated every 3-5 minutes up to a maximum dose of 3 mg, as recommended by the most recent guidelines 1. For symptomatic bradycardia, immediate medical attention is necessary, and the treatment approach depends on the severity of symptoms and underlying cause. Some key points to consider in the treatment of bradycardia include:

  • First-line medication: atropine 0.5 mg IV, which can be repeated every 3-5 minutes up to a maximum dose of 3 mg 1
  • Temporary transcutaneous pacing may be required if atropine is ineffective 1
  • Permanent pacemaker implantation is often the definitive treatment for chronic bradycardia 1
  • Asymptomatic bradycardia typically doesn't require treatment
  • Underlying causes such as medication side effects, hypothyroidism, or electrolyte imbalances should be addressed 1
  • Medications that may be causing bradycardia should be discontinued or dosages adjusted when possible In emergency situations, maintaining airway, breathing, and circulation takes priority while preparing for definitive treatment. It's essential to note that the treatment approach may vary depending on the specific circumstances, and the most recent guidelines should be consulted for the most up-to-date recommendations 1. The use of atropine should be cautious in the presence of acute coronary ischemia or MI, as increased heart rate may worsen ischemia or increase infarction size 1. Overall, the goal of treatment is to improve cardiac output, reduce symptoms, and prevent complications associated with bradycardia.

From the FDA Drug Label

Atropine abolishes various types of reflex vagal cardiac slowing or asystole The drug also prevents or abolishes bradycardia or asystole produced by injection of choline esters, anticholinesterase agents or other parasympathomimetic drugs, and cardiac arrest produced by stimulation of the vagus. Atropine also may lessen the degree of partial heart block when vagal activity is an etiologic factor In some patients with complete heart block, the idioventricular rate may be accelerated by atropine; in others, the rate is stabilized.

Bradycardia treatment with atropine is possible as it can abolish or prevent bradycardia caused by vagal activity.

  • Atropine can increase the heart rate in patients with bradycardia by counteracting the effects of vagal stimulation.
  • The drug may be used to treat bradycardia, especially when it is caused by increased vagal tone or cholinergic agents 2.

From the Research

Bradycardia Treatment Overview

  • Bradycardias are caused by a failure of the sinus node to generate normal impulses or due to a defect in cardiac conduction that in turn causes a delay or failure of impulse propagation 3
  • Treatment is required if symptoms of dizziness, confusion, fatigue, Stokes-Adams attacks, or heart failure occur 3

Treatment Options

  • Sinus node dysfunction or 'sick sinus syndrome' usually requires a permanent pacemaker 3
  • Atrioventricular (AV) conduction disturbances may require a pacemaker if the escape rhythm is unstable 3
  • In critically ill patients, initial resuscitation may involve catecholamines, atropine, aminophylline, and a temporary pacemaker 3

Special Considerations

  • Bradycardias are uncommon in critically ill patients, but may be caused by underlying disorders such as hyperkalaemia, calcium channel blocker toxicity, or beta adrenergic receptor blocker toxicity 3
  • Post cardiac bypass and acute myocardial infarction may cause cardiac conduction defects that require urgent resuscitation with a temporary pacemaker 3

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Cardiac arrhythmias: diagnosis and management. The bradycardias.

Critical care and resuscitation : journal of the Australasian Academy of Critical Care Medicine, 2002

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.